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1. Introduction
Gout is a disease known since before the Common Era. There are reports of urate 
crystal deposition in the big toe joints of an excavated mummy in ancient Egypt. 
There are records of many figures throughout Western history who experienced 
the painful suffering of gout, for example, Alexander the Great of Macedonia, King 
Carlos V of Spain, Frederick the Great of Prussia, Louis XIV of France, Martin 
Luther of the Reformation, Oliver Cromwell of the Puritan Revolution, the artist 
Michelangelo, Leonardo da Vinci, the poets Dante and Milton, the physicist Isaac 
Newton, and the biologist Charles Darwin, among others. In contrast, there is little 
historical evidence of gout in Asia. Yet the disease has become common in modern 
society [1–3]. The prevalence of gout in the past has generally been higher among 
middle-aged men, but in recent years, the number of young people and women 
with gout has been increasing.
2. Pathophysiology
Gout is a metabolic disorder caused by hyperuricemia [4, 5]. Uric acid is the final 
metabolite of purine in humans. Uric acid is produced via hypoxanthine and xan-
thine by the action of xanthine oxidase on purine. Two-thirds of uric acid is excreted 
in the urine and one-third in feces. The amount of serum uric acid is determined by 
the amount produced and the amount excreted in the kidneys. Hyperuricemia occurs 
when the level of serum uric acid rises. In hyperuricemia, when urate crystals pre-
cipitate in the joint cavity and are phagocytosed by leukocytes, crystal-induced gouty 
arthritis develops. The symptoms of crystal-induced arthritis are similar to those of 
rheumatoid arthritis, infectious arthritis, and many collagen diseases, among others. 
Therefore, it is necessary to distinguish among these conditions. Gouty arthritis 
develops as acute monoarthritis, with pain, swelling, redness, and fever, peaking in 
12–24 h. The initial strong inflammation improves in about 2 weeks but can relapse 
if hyperuricemia remains unchecked. If hyperuricemia continues, urate crystals are 
deposited in the joints and connective tissues, activating monocytes or macrophages 
via the Toll-like receptor pathway and innate immune response. Inflammatory 
cytokines including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) are 
secreted, leading to endothelial activation and attraction of neutrophils to the site 
of inflammation. Neutrophils secrete inflammatory mediators that create an acidic 
environment, which causes further precipitation of urate crystals.
3. Classification
Causes of hyperuricemia are classified into primary and secondary hyperuri-
cemia. Primary hyperuricemia is idiopathic. Secondary hyperuricemia can involve 
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hereditary metabolic diseases such as Lesch–Nyhan syndrome, phosphoribosyl-
pyrophosphate synthetase hypertrophy and congenital myogenic hyperuricemia, 
malignant tumors such as malignant lymphoma and breast cancer, psoriasis 
vulgaris, hemolytic anemia, rhabdomyolysis, hypothyroidism, and others. In addi-
tion, drug-induced hyperuricemia owing to anticancer agents, low-dose aspirin, 
loop diuretics, ethambutol, theophylline, and others can be involved in secondary 
hyperuricemia [6, 7].
4. Symptoms
In gouty arthritis, severe pain attacks may also occur in the hallux metatarso-
phalangeal joints, ankle joints, Achilles tendon, knee joints, wrist joints, and other 
sites [8]. When urate crystals precipitate in the joints, acute inflammatory arthritis 
is produced, which causes recurrent episodes of red, tender, swollen joints and leads 
to bone and joint destruction. Gout nodules, or tophi, are most often found in the 
auricle but also form on the elbow, forearm, hallux, Achilles tendon, patella, and so 
on. Tophi are not painful, but if they progress, tophi can lead to joint deformation 
and bone destruction, seriously affecting quality of life. Urate crystal accumulation 
in the kidneys causes severe pain and deterioration of kidney function and renal 
failure. Furthermore, hyperuricemia might be associated with hypertension and 
ischemic heart diseases [9].
5. Management
For effective treatment of acute gout attacks, nonsteroidal anti-inflammatory 
drugs (NSAIDs) or colchicine are administered as soon as possible, as first-line 
treatment options [10]. For patients who do not respond to NSAIDs or colchi-
cine, systemic corticosteroids generally may be applied. In addition, for gouty 
arthritis, joint injection of corticosteroids is often used. For the treatment of 
chronic gout, drugs are used that either promote uric acid excretion, such as 
probenecid, or prevent its synthesis via inhibition of enzyme xanthine oxidase, 
such as allopurinol and febuxostat. If serum uric acid levels fluctuate during gout 
treatment, arthritis may become exacerbated. In addition, if a gout attack occurs 
during drug treatment, the level of serum uric acid should be maintained, that 
is, the amount of uric acid-lowering drugs should not be increased. In such cases, 
NSAIDs, colchicine, and corticosteroids are used for treatment of a gout attack. 
Generally, renal function should be checked before drug treatment because 
gout often occurs in patients with renal impairment. Furthermore, as nondrug 
treatment, extracorporeal shock wave lithotripsy is used to break up kidney and 
ureteral stones. Large gout nodules may be surgically resected. Thus, other treat-
ments for gout are often used in combination with drug therapy.
6. New treatment
Gout is classified within a group of autoinflammatory diseases that includes 
hereditary periodic fever, Muckle-Wells syndrome, familial Mediterranean fever, 
familial cold autoinflammatory syndrome, and pseudogout. In gout, innate immu-
nity is said to act, and acquired immunity is not involved; there is a difference 
between gout and autoimmune diseases such as rheumatoid arthritis or juvenile 
idiopathic arthritis. Recently, newer treatment options have been extensively 
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studied, especially IL-1 inhibitors such as anakinra, canakimumab, and rilonacept. 
Although IL-1 inhibitors are less effective than TNF inhibitors in rheumatoid arthri-
tis, they have become available as a treatment for gout in recent years. Although 
the inflammatory effects of IL-1 are diverse, owing to their therapeutic effect, IL-1 
inhibitors are expected to be widely used in future clinical applications [11]. When 
combined with current traditional therapies, these new agents present more prom-
ising treatment options for clinicians and patients with gout that is difficult to treat.
7. Conclusion
Gout is not a life-threatening illness, but it is characterized by many lifestyle-
related diseases such as obesity, hyperlipidemia, hypertension, and glucose intoler-
ance [12]. All these diseases cause arteriosclerosis; therefore, it is necessary to treat 
gout carefully. All physicians in clinical practice should know about the treatment 
and prevention of gout. The treatment goal for gout is to provide effective methods 
of treatment and prevention and to provide patients with good health-related 
quality of life. However, long time is required to improve serum uric acid levels 
and to manage gout attacks. In this book, each expert reports on gout based on the 
evidence and their own research. It is my hope that this book will be helpful in your 
clinical practice.
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